HDL Apomics is looking at a new way to measure and develop pharmaceutical treatments in the cardiovascular theropeutic area by analyzing HDL.

• Technology Presenter: Scott Altmann
• Accelerator-Commercial Catalyst: Caroline Hoedemaker, VALUEDsolutions
• Defined Milestone: Prepare for fall Commercial Presentations to the Pharmaceutical Industry
• Targeted Completion: 1 months